FDA Panel Will Bring A SHARP Eye To Vytorin, Zetia sNDAs For Chronic Kidney Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Nov. 2 to discuss whether the SHARP study results support use of the cholesterol-lowering agents for cardiovascular risk reduction in patients with renal disease.